Lupin just dropped a molecule mic at ASCO 2025, presenting Phase 1a data for LNP7457, a novel PRMT5 inhibitor targeting advanced/metastatic solid tumors. The early results? Safe, tolerable, food-independent, and headed for Phase 1b in India.
Now the question is: Will this SAM-competitive molecule be Lupin’s Keytruda moment — or just another biotech poster child with a fancy DOI and no commercial payoff?
🧪 What Is LNP7457? (Without Sounding Like a PhD)
It’s a PRMT5 inhibitor, a class of epigenetic therapies disrupting how cancer cells “turn on” survival genes
PRMT5 (Protein Arginine Methyltransferase 5) = often overexpressed in cancer cells
LNP7457 is SAM-competitive — it blocks the binding site for the methyl donor, essentially cutting off the fuel for tumor growth
👉 Think of it as a precision sniper, not a shotgun like chemo
